Taysha Gene Therapies, Inc. (NASDAQ: TSHA) Stock Information | RedChip

Taysha Gene Therapies, Inc. (NASDAQ: TSHA)


$1.7650
-0.1650 ( -5.62% ) 843.8K

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Market Data


Open


$1.7650

Previous close


$1.9300

Volume


843.8K

Market cap


$361.73M

Day range


$1.7250 - $1.8950

52 week range


$1.1900 - $4.3200

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jan 03, 2025
4 Insider transactions 1 Jan 03, 2025
4 Insider transactions 1 Jan 03, 2025
10-q Quarterly Reports 97 Nov 13, 2024
8-k 8K-related 14 Nov 13, 2024
8-k 8K-related 14 Aug 12, 2024
10-q Quarterly Reports 98 Aug 12, 2024
4 Insider transactions 1 Jul 01, 2024
8-k 8K-related 19 Jun 26, 2024
8-k 8K-related 29 Jun 26, 2024

Latest News